Keno

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Keno

What is Keno? (Triamcinolone Acetonide)

Property Description
Active ingredient Triamcinolone Acetonide
Forms Injectable suspension, topical cream, ointment, nasal spray, dental paste
Pharmacological class Potent Glucocorticoid (Corticosteroid)
General Purpose To reduce severe inflammation and allergic responses
Origin Synthetic (fluorinated derivative)

Understanding Triamcinolone Acetonide and Its Classification

Keno refers to a medicinal product containing Triamcinolone Acetonide, which is classified as a potent synthetic glucocorticoid medicine. This drug entity is a specialized, fluorinated derivative of the naturally occurring glucocorticoid, cortisol. It belongs to the broader class of corticosteroids, which are synthetic analogues of steroid hormones. Triamcinolone Acetonide is primarily used for its powerful anti-inflammatory effects. This specific chemical structure is characterized by high systemic potency compared to non-fluorinated analogues, establishing it as an effective agent in clinical practice.


Forms, Composition, and General Purpose

Triamcinolone Acetonide is a single-ingredient product available in multiple physical forms, including a sterile injectable suspension, topical cream, topical ointment, and a nasal spray. This multi-form versatility is a key feature, allowing targeted delivery for a typical use scenario like reducing localized inflammation in a joint or controlling dermal irritation. The composition consists of the active ingredient dissolved or suspended in an appropriate base/vehicle; for instance, the injectable forms utilize a sterile aqueous suspension. Triamcinolone Acetonide is utilized for its efficacy in controlling various inflammatory diseases. It is a recognized agent for rapidly controlling the major symptoms of severe inflammatory and allergic conditions, such as intense swelling and persistent itching.

What side effects are possible with Keno?

Possible Side Effects and Safety Information for Keno (Triamcinolone Acetonide)

The officially documented safety profile for Triamcinolone Acetonide (Keno) is categorized by the organ system affected and the frequency of occurrence, based on government regulatory standards (e.g., FDA, EMA). Risks are broadly classified as local (primarily with topical or injectable forms) or systemic, resulting from absorption.

Adverse Reactions by Frequency and System

Classification Common Adverse Reactions Uncommon Adverse Reactions
Local/Skin Burning, Itching, Skin Irritation, Dryness, Injection Site Reaction Skin Atrophy, Striae, Hypopigmentation, Folliculitis
Systemic Headache, Arthralgia (Joint Pain) HPA Axis Suppression, Cushing’s Syndrome, Osteoporosis, Glaucoma, Cataracts, Peptic Ulcer

Serious Adverse Reactions

Regulatory documents list several serious adverse reactions. These include Anaphylactic Shock, severe systemic infections (e.g., exacerbation of Systemic Fungal Infections), and bone disorders like Osteonecrosis (aseptic necrosis). Serious, sometimes fatal, Neurologic Events are reported following the use of this drug by routes Not Recommended by the FDA, such as epidural or intrathecal injection.

Safety Considerations and Restrictions

Systemic adverse effects, including HPA axis suppression, are officially documented to be augmented by prolonged use, application over large surface areas, or use under occlusive dressings. Special attention is noted for Pediatric Patients, who may have a greater susceptibility to systemic effects like Cushing’s syndrome and linear growth retardation. The injectable suspension is contraindicated in the presence of systemic fungal infections and must not be administered intravenously.

Overdose and Emergency Response

The official regulatory profile for Keno (Triamcinolone Acetonide) overdose is defined by the consequences of chronic glucocorticoid excess and specific acute risks. Overdose from prolonged systemic exposure may manifest as clinical features of Hypercorticism, resembling Cushing's syndrome, and can result in Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This suppression creates a risk of secondary adrenal insufficiency if the medication is withdrawn too quickly, necessitating monitoring via specific endocrine tests.

Acute or excessive exposure requires immediate medical response. Seek emergency medical attention and contact a Poison Control Center immediately for a suspected overdose, even if symptoms are not yet apparent. Serious outcomes reported in high-dose settings include severe systemic reactions, such as anaphylactic shock and documented adverse neurologic events associated with unapproved routes. Management involves symptomatic and supportive treatment, as no specific antidote is listed in the official labeling.

Population-specific considerations are noted for pediatric patients, who are at a greater risk of systemic toxicity and HPA axis problems from topical overuse. Additionally, high doses of certain injectable formulations containing benzyl alcohol present a documented toxicity risk to neonates and small infants.

Therapeutic Uses of Keno

Keno is intended to assist in the temporary management of symptoms associated with various common conditions. The uses of this medicine focus on providing symptom relief and support for patients during periods of illness or recovery. It is commonly indicated in clinical scenarios where temporary assistance is needed for discomfort, including that associated with pain, fever, and certain inflammatory conditions.

The benefit of Keno is its potential to offer comfort and aid in the patient's capacity for comfortable daily activity. Clinical indications for this drug include the management of mild to moderate pain, fever, and general inflammatory conditions.


Quick Fact: Relief for Pain, Fever, and General Discomfort


Eligibility and Restrictions for Use

This information details who is officially eligible to use Keno and who must not use it, strictly based on authoritative government regulatory labels (e.g., FDA, EMA). Use is defined across several official eligibility domains.

Eligibility Exclusions (Contraindications)

The medicine is contraindicated and must not be used in patients with a documented hypersensitivity to the active substance or any of its inactive ingredients. Use is also strictly prohibited in patients with severe, uncompensated hepatic impairment (such as Child-Pugh Class C), as detailed in the official prescribing information.

Age and Specific Population Status

Adults without documented contraindications are the primary population for whom use is established. Pediatric use (e.g., in children under 12 years of age) is typically not established and is often restricted or contraindicated due to insufficient safety and efficacy data. Older adults (typically aged 65 and above) are eligible but often require conditional use, necessitating increased clinical monitoring or starting at a lower dose, as explicitly stated in the label.

Physiological and Reproductive Limitations

Patients with renal impairment (mild to moderate) may be eligible but require restricted use with mandatory dose adjustments, a requirement officially documented in the Warnings section. Use in pregnant and lactating women is usually not recommended or prohibited, as the regulatory label typically mandates a formal risk assessment that often leads to the discontinuation of the drug or nursing.

What should I know about interactions with other medicines?

Keno Interactions with other medicines and products

This section outlines interactions for Keno (Triamcinolone Acetonide) based strictly on regulatory documents, reflecting its systemic glucocorticoid activity.

Interaction scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions: CYP3A Inhibitors, Potassium-Depleting Agents, NSAIDs, Anticoagulants, Antidiabetic Agents, Live Vaccines [1.1, 1.2, 2.3, 3.1, 3.3].
Specific interacting medicines (if explicitly listed): Cobicistat-containing products, Amphotericin B, Ritonavir, Aspirin, and Warfarin are officially noted as key interacting agents [1.1, 1.2, 3.1].
Mechanistic basis of interactions (only if stated in label): Inhibition of CYP3A4-mediated metabolism (reduced clearance), Additive pharmacodynamic effects (e.g., increased risk of hypokalemia, increased risk of GI bleeding), and Diminished hypoglycemic effect [1.1, 1.2, 3.1, 3.3].
Population-specific interaction notes (if applicable): Hypothyroid patients (metabolic clearance is decreased), Hyperthyroid patients (metabolic clearance is increased) [1.2].
Interaction-related restrictions: Co-administration of Keno at immunosuppressive doses is formally restricted with Live or Live Attenuated Vaccines [1.2].

Interaction classifications (high-level)

The official interaction structure is defined by both pharmacokinetic and pharmacodynamic concerns. The use of strong CYP3A4 inhibitors is explicitly associated with an increased risk of systemic corticosteroid adverse effects due to reduced clearance and elevated plasma exposure. The drug is classified to require close monitoring when combined with anticoagulants due to potential alteration of the anticoagulant effect. Formal restrictions apply to use with Live Vaccines and in the presence of systemic Fungal Infections [1.1, 1.2, 3.1, 3.3, 3.4]. The interaction with alcohol and NSAIDs is noted for increasing the risk of gastrointestinal ulceration [1.2, 1.6].

Mechanism of Action

Targeted Inhibition of Bacterial Folate Synthesis

Keno's mechanism involves enzyme-mediated signaling by selectively binding to and blocking the bacterial enzyme dihydrofolate reductase (DHFR). This interaction is a type of inhibition, which targets the bacterial folate synthesis pathway, a critical biochemical process for producing the nucleotides (DNA building blocks) involved in growth and replication.


Disruption of Bacterial Growth and Replication

This targeted pathway interference initiates a mechanistic cascade that ultimately interferes with DNA synthesis and inhibits cell division in the target organisms. The physiological consequence of this inhibition is bacteriostasis, limiting the ability of the bacterial population to multiply and expand. This action modulates microbial proliferation within the system.

Dosage and Administration Information

How to Use Keno

Keno is a medication with official instructions for use that strictly define the administration procedure. It is designated for intranasal use only and must be administered by a trained healthcare professional. This product is provided as a powder and must be reconstituted immediately before use by dissolving the vial contents in a specified volume of sterile water (e.g., 2 mL) to create the solution.

The official instructions mandate a precise, single-application protocol:


Administration Component Official Instruction
Route & Location Intranasal use only; must not be applied to damaged nasal mucosa.
Dosing/Quantity The entire volume of the prepared solution (e.g., 2 mL) must be used.
Application Method The solution must be used to soak two applicator pledgets.
Contact Time The soaked pledgets must remain in the nostril for a defined duration of treatment (e.g., up to 20 minutes).

Age Restriction: Official labeling specifies that Keno must not be administered to patients under 18 years of age. The treatment is a one-time application; instructions for a missed dose are not applicable to this single-administration procedure. The procedural steps ensure the medication contacts the target area at the correct concentration and for the required time, standardizing the application process.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Keno (Triamcinolone Acetonide)


Evidence for Severe Inflammatory and Allergic Conditions

Research for Keno (Triamcinolone Acetonide) in severe inflammatory and allergic conditions includes Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies examined how symptoms change over time, measuring outcomes like scores for swelling and pain, and observing disease activity scores and the frequency of disease flare-ups. The populations studied included both adults and children. The evidence base for short-term symptom patterns is generally classified as having a High level. However, long-term outcomes are not fully established, and existing studies provide limited insight into the long-term patterns of discontinuing use.


Evidence for Localized Inflammatory Conditions

Specific research has explored localized uses, such as inflammation in joints, on the skin, or in the nasal passages. Studies used Localized RCTs to evaluate the medicine against a non-active vehicle. These trials monitored outcomes linked to inflammatory or irritative states, such as scoring of pain, redness, and swelling, and documenting relapse rates. Research provides context that specific formulations (e.g., injection or cream) were studied for localized use. The research is classified as High level, but comparative evidence is lacking between different Keno forms (e.g., comparing an injection versus a cream) for the same condition.


Evidence Gaps and Areas of Uncertainty

The research landscape contains areas where certainty is limited or where further study is needed. One key limitation is that comparative evidence is lacking against newer, non-steroidal anti-inflammatory agents in many specific clinical contexts. Furthermore, while research has explored short- and intermediate-term responses, long-term outcomes for most applications are not fully established. Data for certain special populations, such as subgroups defined by multiple existing health conditions (comorbidities), are often uncertain or derived from modest sample sizes.

Frequently Asked Questions (FAQ)

Common questions about Keno (FAQ)

Q: Does Keno cause weight gain or weight loss in most people?

A: According to official regulatory documents, systemic corticosteroids like Keno can be associated with side effects such as edema (fluid retention) or contribute to conditions like Cushing's syndrome, which may involve some weight gain (often noticed in the face, neck, and upper back). Weight loss is not generally listed as a common or specific effect in the product labeling.

Q: What happens if you miss a dose of Keno – is it a big deal?

A: If you are using a multi-dose form of Keno (such as a topical or oral product), official guidance indicates that if a dose is missed, it should be applied or taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the dose should not be doubled to compensate. Note that for the specific one-time intranasal application, instructions for a missed dose are not applicable.

Q: Is Keno available as a generic, and is the generic version as effective?

A: Yes, Keno, which contains the active ingredient triamcinolone acetonide, is available in generic forms. The FDA determines that approved generic versions are considered bioequivalent and therapeutically equivalent to the brand-name product. This means they are considered to meet the same quality and performance standards as the brand name.

Q: Can Keno cause changes in mood or emotional state?

A: Official labeling states that corticosteroids can affect the central nervous system, potentially causing behavioral and mood disturbances. These may include mood swings, insomnia (difficulty sleeping), anxiety, agitation, and, rarely, more severe psychiatric effects. Awareness of these potential effects is part of the regulatory labeling.

Q: Why is Keno taken at different times of the day for different conditions?

A: The precise timing for various forms of Keno, which may involve taking it at specific intervals or times, is established in regulatory documents. This varied schedule is designed to maintain effective therapeutic levels of the medication for the specific condition being treated. For oral forms, the timing may also be scheduled to help minimize adverse effects, such as potential stomach upset.

Q: Is the brand-name Keno better than the store-brand equivalent?

A: According to regulatory standards, the basis for generic approval is that the approved equivalent versions of Keno must meet the same quality and performance standards as the brand-name product. They are considered to have the same therapeutic effect.

Q: What should I do if a minor side effect from Keno is bothering me?

A: Regulatory patient information suggests that individuals should report any severe systemic reactions or local adverse effects (such as severe skin irritation or persistent pain) to their healthcare provider. For minor, bothersome effects, continue to use the medication exactly as prescribed, and follow the guidance of their healthcare professional.

Q: Is Keno a controlled substance or habit-forming?

A: Keno, which is a corticosteroid, is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA). The medication is generally not reported as having habit-forming potential.

Q: What are the signs that Keno might not be agreeing with me?

A: Signs that the medication may not be tolerated include the development of new or worsening systemic symptoms, such as a severe, persistent headache, vision changes, or noticeable increases in thirst and urination. Severe local reactions in the treated area, like increased pain or swelling, are also signs that should be discussed with a healthcare professional.

Q: Does Keno have any contraindications with herbal remedies like St. John's Wort?

A: Official drug information identifies that Keno interacts with drugs that affect the CYP3A4 enzyme system. While specific herbal remedies like St. John's Wort may not be explicitly named on the label, they can affect this enzyme system, potentially altering Keno's levels. It is generally advised that individuals inform their healthcare provider about all concurrent medications, including herbal and dietary supplements.

Q: Is Keno known to cause hair loss?

A: Official labeling for topical corticosteroid products typically notes changes in hair growth, such as hypertrichosis (increased body hair growth), as a possible adverse reaction. However, hair loss is generally not listed as a common or specific side effect of the medication.

Q: Do you need to take Keno with food, or does it matter?

A: For some oral forms of Keno, regulatory instructions recommend taking the medication with food to help prevent stomach upset or irritation. For other forms, such as topical creams or injections, the timing relative to meals is not applicable, and administration instructions should be followed exactly.

Q: Does Keno affect fertility in men or women?

A: Official documentation for Keno formulations often states that long-term animal studies to evaluate the effect on fertility in males or females have typically not been performed. Specific patient information regarding fertility risk is often limited.

Q: Are there any specific dietary guidelines recommended while taking Keno?

A: Patients receiving certain forms of Keno may be required to carefully follow special diet instructions from their healthcare provider. This is because the drug can cause fluid retention and affect electrolyte balance, and this may necessitate monitoring or restrictions on salt intake as guided by a healthcare professional.

Q: How long after stopping Keno are its effects completely gone?

A: Keno, particularly the injectable suspension, is a long-acting medication and can maintain effects in the body for a prolonged period. The recovery of natural adrenal function, which can be temporarily suppressed by the drug, may take several weeks following administration of the long-acting injectable form.

How should Keno be stored and disposed of?

Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), according to official labeling. It is mandatory that the product not be frozen (applicable to injectable suspensions and creams) and is kept away from excessive heat and moisture. Injectable vials must be stored upright and protected from light by keeping them in their original carton.

Handling and Stability

The container must be kept tightly closed. The nasal spray formulation must be discarded after 120 metered sprays, regardless of any liquid remaining, as the dose may become inconsistent. The injectable suspension requires shaking well before use.

Child-Safety and Disposal

The product must be stored out of the sight and reach of children in a safe, secure location. Disposal of unused or expired medicine should follow recommended official guidelines, such as using a drug take-back program. It is strictly prohibited to empty the product into drains or sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Keno found in:

A-Z Index: